FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Pete O'Heeron will engage in a fireside chat on October 16, 2024, at 10:00 a.m. ET.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Based in Houston, FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, interested parties can visit the company's website or contact them directly via email.
FibroBiologics (Nasdaq: FBLG), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Il CEO Pete O'Heeron parteciperà a una chiacchierata informale il 16 ottobre 2024, alle 10:00 a.m. ET.
FibroBiologics è specializzata nello sviluppo di terapie e potenziali cure per malattie croniche utilizzando fibroblasti e materiali derivati dai fibroblasti. L'azienda vanta oltre 160 brevetti concessi e in attesa in diversi percorsi clinici, tra cui la degenerazione del disco, ortopedia, sclerosi multipla, psoriasi, guarigione delle ferite, inversione dell'involuzione degli organi e cancro.
Con sede a Houston, FibroBiologics rappresenta la nuova generazione di avanzamenti medici nella terapia cellulare. Per ulteriori informazioni, le parti interessate possono visitare il sito web dell'azienda o contattarli direttamente via email.
FibroBiologics (Nasdaq: FBLG), una empresa biotecnológica en etapa clínica, anunció su participación en el 2024 Maxim Healthcare Virtual Summit. El CEO Pete O'Heeron participará en una charla informal el 16 de octubre de 2024, a las 10:00 a.m. ET.
FibroBiologics se especializa en el desarrollo de terapias y posibles curas para enfermedades crónicas utilizando fibroblastos y materiales derivados de fibroblastos. La empresa cuenta con más de 160 patentes otorgadas y pendientes en diversos caminos clínicos, incluyendo degeneración de discos, ortopedia, esclerosis múltiple, psoriasis, curación de heridas, inversión de la involución de órganos y cáncer.
Con sede en Houston, FibroBiologics representa la próxima generación de avances médicos en terapia celular. Para más información, las partes interesadas pueden visitar el sitio web de la empresa o contactarlos directamente por correo electrónico.
FibroBiologics (Nasdaq: FBLG), 임상 단계의 생명공학 회사가 2024 Maxim Healthcare Virtual Summit에 참석한다고 발표했습니다. CEO Pete O'Heeron은 2024년 10월 16일, 오전 10시 ET에 대화에 참여할 예정입니다.
FibroBiologics는 섬유아세포 및 섬유아세포 유래 소재를 사용하여 만성 질환에 대한 치료제와 잠재적인 치료법을 개발하는 데 전문화되어 있습니다. 이 회사는 디스크 퇴행, 정형외과, 다발성 경화증, 건선, 상처 치유, 장기 위축 반대 및 암을 포함한 다양한 임상 경로에서 160개 이상의 등록 및 출원된 특허를 보유하고 있습니다.
휴스턴에 본사를 둔 FibroBiologics는 세포 치료의 다음 세대 의료 발전을 나타냅니다. 자세한 정보는 회사 웹사이트를 방문하거나 직접 이메일로 연락하면 됩니다.
FibroBiologics (Nasdaq: FBLG), une entreprise de biotechnologie en phase clinique, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Le PDG Pete O'Heeron participera à une discussion informelle le 16 octobre 2024 à 10h00 ET.
FibroBiologics est spécialisée dans le développement de thérapies et de cures potentielles pour les maladies chroniques en utilisant des fibroblastes et des matériaux dérivés des fibroblastes. L'entreprise dispose de plus de 160 brevets délivrés et en attente dans divers domaines cliniques, notamment la dégénérescence des disques, l'orthopédie, la sclérose en plaques, le psoriasis, la cicatrisation des plaies, l'inversion de l'involution organique et le cancer.
Basée à Houston, FibroBiologics représente la prochaine génération d'avancées médicales en thérapie cellulaire. Pour plus d'informations, les personnes intéressées peuvent visiter le site Web de l'entreprise ou les contacter directement par e-mail.
FibroBiologics (Nasdaq: FBLG), ein biopharmazeutisches Unternehmen in der klinischen Phase, gab seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt. CEO Pete O'Heeron wird am 16. Oktober 2024 um 10:00 Uhr ET an einem persönlichen Gespräch teilnehmen.
FibroBiologics hat sich auf die Entwicklung von Therapeutika und potenziellen Heilmitteln für chronische Krankheiten spezialisiert, die Fibroblasten und aus Fibroblasten abgeleitete Materialien nutzen. Das Unternehmen verfügt über über 160 erteilte und anhängige Patente in verschiedenen klinischen Bereichen, darunter Bandscheibendegeneration, Orthopädie, Multiple Sklerose, Psoriasis, Wundheilung, Umkehrung der Organinvolution und Krebs.
Mit Sitz in Houston repräsentiert FibroBiologics die nächste Generation medizinischer Fortschritte in der zelltherapeutischen Behandlung. Weitere Informationen erhalten Interessierte auf der Unternehmenswebsite oder können sie direkt per E-Mail kontaktieren.
- None.
- None.
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O’Heeron, Chief Executive Officer of FibroBiologics, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET.
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When is FibroBiologics (FBLG) participating in the 2024 Maxim Healthcare Virtual Summit?
What is FibroBiologics' (FBLG) main focus in biotechnology?
How many patents does FibroBiologics (FBLG) hold?
What clinical pathways does FibroBiologics (FBLG) research cover?
Who will represent FibroBiologics (FBLG) at the 2024 Maxim Healthcare Virtual Summit?
